The Efficacy and Safety of Anti-PD-1 Antibody Camrelizumab Combined With Apatinib for Neoadjuvant Therapy in Locally Advanced Thyroid Cancer: a Phase II Study
Latest Information Update: 04 Jan 2024
At a glance
- Drugs Camrelizumab (Primary) ; Rivoceranib (Primary)
- Indications Thyroid cancer
- Focus Therapeutic Use
- 04 Nov 2020 New trial record